Compare WSBF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSBF | PRTA |
|---|---|---|
| Founded | 1921 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.8M | 449.7M |
| IPO Year | 2013 | 2013 |
| Metric | WSBF | PRTA |
|---|---|---|
| Price | $21.28 | $9.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 50.9K | ★ 357.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ 46.53 | N/A |
| EPS | ★ 0.84 | 0.26 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $25.27 | $37.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.52 | $7.73 |
| 52 Week High | $21.50 | $11.80 |
| Indicator | WSBF | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 62.19 |
| Support Level | $20.45 | $8.10 |
| Resistance Level | N/A | $10.11 |
| Average True Range (ATR) | 0.39 | 0.37 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 100.00 | 90.32 |
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.